Biologics have greatly improved the standard of care for psoriasis, but start-ups see real opportunity in new oral and topical treatments.
Avexxin AS is betting that the novel molecular target identified by one of its co-founders will enable development of...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?